1-3 of 3
Stefan Balabanov, M.D., Ph.D
Close
Sort by
Journal Articles

Simultaneous Targeting of Aurora Kinases and Bcr-Abl by the Small Molecule Inhibitor PHA-739358 Is Effective in Imatinib-Resistant Mutations Including T315I.

Artur Gontarewicz, MD, Stefan Balabanov, M.D., Ph.D., Gunhild Keller, M.D., Riccardo Colombo, Ph.D., Alessio Graziano, Ph.D, Carsten Bokemeyer, M.D., Walter Fiedler, M.D., Jurgen Moll, Ph.D., Tim Brummendorf, M.D.
Journal: Blood
Blood (2007) 110 (11): 1042.
https://doi.org/10.1182/blood.V110.11.1042.1042
Published: 2007
Journal Articles

Effective Telomerase Inhibition Via Expression of Dominant-Negative HTERT Leads to Altered Growth Kinetics, Elevated Apoptosis and Increased Radiosensitivity of Bcr-Abl-Positive K562 Cells In Vitro.

Ute Brassat, Stefan Balabanov, M.D., Ph.D., Henning Wege, M.D., Daniel Roessler, Kerstin Borgmann, M.D., Tim Brummendorf, MD
Journal: Blood
Blood (2007) 110 (11): 2935.
https://doi.org/10.1182/blood.V110.11.2935.2935
Published: 2007
Journal Articles

PHA-680626 Exhibits Anti-Proliferative and Pro-Apoptotic Activity on Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines and Primary CD34+ Cells by Inhibition of Both Bcr-Abl Tyrosine Kinase and Aurora Kinases.

Artur Gontarewicz, MD, Stefan Balabanov, M.D., Ph.D, Gunhild Keller, M.D., Jens Panse, M.D., Mirja Bernhardt, Carsten Bokemeyer, M.D., Walter Fiedler, M.D., Jurgen Moll, Ph.D., Tim Brummendorf, M.D.
Journal: Blood
Blood (2007) 110 (11): 4568.
https://doi.org/10.1182/blood.V110.11.4568.4568
Published: 2007